Can anyone with a genuine medical / statistical understanding of this material explain why IMU would not have (or would not have been able to) provide an update to the 14.2 month OS figure reported in November?
No arguing with a 5.4 month OS benefit and understand that HER-Vaxx doesn't add any harmful side effects, but boiled down, the patient is still on chemo (and all the harmful side effects that that causes). A wealthy patient would no doubt pay for HER-Vaxx, but would a health system provide reimbursement for this 5.4 month benefit?
I couldn't find anything new in the announcement. The material about anti body levels and superiority to chemo alone seems to have already been captured in the overall survival figure reported in November. Interested to hear why this assumption may be incorrect ...
IMU Price at posting:
18.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)